NorthStrive files two patent applications for muscle preservation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets
June 18, 2026 7:30 AM EDTFiled applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight lossFiled applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support
NEWPORT BEACH, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary, NorthStrive Biosciences, Inc. ("NorthStrive"), has filed two new U.S. patent applications expanding the Company's EL-22... More
